HEMATOLOGÍA

2011

Artículos

Albizua E, Gallardo M, Barrio S, Rapado I, Jiménez A, Ayala R, et al. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. Ann Hematol. 2011;90(8):939-46.

Alegre A, Aguado B, Giraldo P, Ríos E, Cánovas A, Ibáñez Á, et al. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. Int J Hematol. 2011;93(3):351-60.

Ayala R, Martínez López J, Cedena T, Bustelos R, Jiménez C, Moreno E, et al. Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. BMC Gastroenterol. 2011;11:130.

Barrio S, Gallardo M, Albizua E, Jiménez A, Rapado I, Ayala R, et al. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. J Clin Pathol. 2011;64(11):1010-3.

Linares M, Albizua E, Méndez D, Rubio JM, Martínez Serna A, Martínez MA, et al. Malaria hidden in a patient with diffuse large-B-cell lymphoma and sickle-cell trait. J Clin Microbiol. 2011;49(12):4401-4.

Martínez López J, Blade J, Mateos MV, Grande C, Alegre A, García Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529-34.

Rivero A, Rapado I, Tomás JF, Montalbán C, De Oña R, Paz Carreira J, et al. Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. Leuk Res. 2011;35(4):431-7.

Sierra Hidalgo F, Ruíz J, Morales Cartagena A, Martínez Salio A, Serna J, Hernández Gallego J. Infiltrative cervical lesions causing symptomatic occipital neuralgia. Cephalalgia. 2011;31(14):1493-6.

.

2012

Artículos

Ayala R, Grande S, Bustelos R, Ribera C, García Sesma A, Jiménez C, et al. Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. BMC Gastroenterol. 2012;12:114.

Bornstein R, Macías MI, De la Torre P, Grande J, Flores AI. Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional three-dimensional structures. Cytotherapy. 2012;14(10):1182-92.

Sopeña M, Clavero EM, Villa P, Martínez López J. Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma. Ther Adv Hematol. 2012;3(3):147-54.

.

2013

Artículos

Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, et al. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood. 2013;122(8):1448-54 [PubMed]

Arranz R, García Noblejas A, Grande C, Cannata Ortiz J, Sánchez JJ, García Marco J-A, et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica. 2013;98(10):1563-70 [PubMed]

Avet Loiseau H, Durie BGM, Cavo M, Attal M, Gutierrez N, Haessler J, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27(3):711-7 [PubMed]

Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, et al. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. Br J Haematol 2013;161(5):667-76 [PubMed]

Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, et al. Intravenous Busulfan and Melphalan as a Conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myelotha: A matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013;19(1):69-74 [PubMed]

Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980-7 [PubMed]

Castellanos González M, Velasco Rodríguez D, Blanco Echevarría A, Postigo C, Ortiz Romero P, Díaz RA, et al. Eosinophilic fasciitis as a manifestation of a cutaneous t-cell lymphoma not otherwise specified. Am J Dermatopathol. 2013;35(6):666-70 [PubMed]

De la Serna J, Jarque I, López Jiménez J, Fernández Navarro JM, Gómez V, Jurado M, et al. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles. Rev Esp Quimioter. 2013;26(1):64-9 [PubMed] [texto completo]

Fernández de Larrea C, Kyle RA, Durie BGM, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27(4):780-91 [PubMed]

Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, García Alonso L, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol. 2013;92(1):19-24 [PubMed]

Gallardo M, Barrio S, Fernández M, Paradela A, Arenas A, Toldos O, et al. Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. Mol Cancer. 2013;12(1):142 [PubMed]

Gonzalo Gil E, Criado G, Santiago B, Dotor J, Pablos JL, Galindo M. Transforming growth factor (TGF)-β signalling is increased in rheumatoid synovium but TGF-β blockade does not modify experimental arthritis. Clin Exp Immunol. 2013;174(2):245-55 [PubMed]

López E, López I, Ferreira A, Sequí J. Retraction: clinical and technical phosphoproteomic research. Proteome Sci. 2013;11(1):16 [PubMed]

Martínez López J, Fernández Redondo E, García Sanz R, Montalbán MA, Martínez Sánchez P, Pavia B, et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol. 2013;163(5):581-9 [PubMed]

Mateos MV, Hernández MT, Giraldo P, De la Rubia J, De Arriba F, López Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438-47 [PubMed]

Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-66 [PubMed]

Paiva B, Vídriales MB, Rosiñol L, Martínez López J, Mateos MV, Ocio EM, et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia. 2013;27(10):2056-61 [PubMed]

Parrondo J, Grande C, Ibáñez J, Palau J, Páramo JA, Villa G. Evaluación económica del tratamiento de la trombocitopenia inmune primaria crónica refractaria con agonistas del receptor de la trombopoyetina. Farm Hosp. 2013;37(3):182-91 [PubMed]

Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, Fernández Giménez C, García Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematol-Hematol J. 2013;98(1):79-86 [PubMed]

Preiser JC, León-Sanz M. Reduced cortisol metabolism during critical illness. N Engl J Med. 2013 Aug 1;369(5):479-80. [PubMed]

Puchades Carrasco L, Lecumberri R, Martínez López J, Lahuerta JJ, Mateos MV, Prósper F, et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res. 2013;19(17):4770-9 [PubMed]

Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status final results of a phase 2 study (Burkimab). Cancer. 2013;119(9):1660-8 [PubMed]

Río Machín A, Ferreira BI, Henry T, Gómez López G, Agirre X, Álvarez S, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013;27(4):925-31 [PubMed]

Sánchez Castro J, Marco Betés V, Gómez Arbonés X, Arenillas L, Valcarcel D, Vallespí T, et al. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leuk Res. 2013;37(7):769-76 [PubMed]

Sarasquete ME, Martínez López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, et al. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. Br J Haematol. 2013;163(2):223-34 [PubMed]

Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279-87 [PubMed]

Valcárcel D, Adema V, Sole F, Ortega M, Nomdedeu B, Sanz G, et al. Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome. J Clin Oncol. 2013;31(7):916-22 [PubMed]

Congresos

Giraldo P, De La Serna J, Espinos B. Cost-utility of velaglucerase alpha for the treatment of type I gaucher disease in Spain. Value Health. 2013;16(3):A119 [ISPOR Annual International Meeting (18. New Orleans, LA. 2013)]

Van Beurden-Tan C, Rosinol L, Diels J, Wirth D, Chirita O, Lahuerta JJ, et al. Cost-effectiveness of induction treatment with bortezomib added to thalidomide and dexamethasone in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation in Germany. Value Health. 2013;16(7):A409-10 [International Society for Pharmacoeconomics and Outcomes Research Annual European Congress (16. Dublin, Ireland, 2013)]

.

2014

Artículos

Ayala R, Rapado I, Grande S, Moreno E, Martínez López J. JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis. Eur J Gastroenterol Hepatol. 2014;26(3):362-3 [PubMed]
JCR Factor de Impacto: 2,253
JCR Cuartil: Q3
JCR Decil: D7
JCR Posición: 47/76
JCR Categoría: GASTROENTEROLOGY & HEPATOLOGY

Bennett TA, Montesinos P, Moscardo F, Martínez Cuadrón D, Martínez J, Sierra J, et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014;14(4):305-18 [PubMed]
JCR Factor de Impacto: 2,020
JCR Cuartil: Q3
JCR Decil: D8
JCR Posición: 48/68
JCR Categoría: HEMATOLOGY

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014;99(7):e126 [PubMed]
JCR Factor de Impacto: 5,814
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 6/68
JCR Categoría: HEMATOLOGY

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-10 [PubMed]
JCR Factor de Impacto: 55,873
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 1/154
JCR Categoría: MEDICINE, GENERAL & INTERNAL

Grande García C, Martínez Martínez R, Valcárcel Ferreiras D, Grupo de estudio de Trombocitopenia Inmune Primaria de la Sociedad Española de Hematología y Hemoterapia y Sociedad Española de Trombosis y Hemostasia. Comparación de guías internacionales sobre púrpura trombocitopénica autoinmunitaria primaria. Med Clin (Barc). 2014;143(9):408-19 [PubMed]

JCR Factor de Impacto: 1,417
JCR Cuartil: Q2
JCR Decil: D5
JCR Posición: 76/155
JCR Categoría: MEDICINE, GENERAL & INTERNAL

Hernández Boluda JC, Pereira A, Gómez M, Boque C, Ferrer Marín F, Raya JM, et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica. 2014;99(4):E55-7 [PubMed]
JCR Factor de Impacto: 5,814
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 6/68
JCR Categoría: HEMATOLOGY

Lippert E, Mansier O, Migeon M, Denys B, Nilsson A, Rosmond C, et al. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. Haematologica. 2014;99(7):e98-101 [PubMed]
JCR Factor de Impacto: 5,814
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 6/68
JCR Categoría: HEMATOLOGY

López Corral L, Corchete LA, Sarasquete ME, Mateos MV, García Sanz R, Fermiñán E, et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica. 2014;99(8):1365-72 [PubMed]
JCR Factor de Impacto: 5,814
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 6/68
JCR Categoría: HEMATOLOGY

Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltrán S, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia. 2014;28(6):1334-40 [PubMed]
JCR Factor de Impacto: 10,431
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 9/211
JCR Categoría: ONCOLOGY

Martínez López J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-9 [PubMed]
JCR Factor de Impacto: 10,452
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 2/68
JCR Categoría: HEMATOLOGY

Martino A, Campa D, Jurczyszyn A, Martínez López J, Moreno MJ, Varkonyi J, et al. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations – an extensive replication of the associations from the candidate gene era. Cancer Epidemiol Biomarkers Prev. 2014;23(4):670-4 [PubMed]
JCR Factor de Impacto: 4,125
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 12/142
JCR Categoría: PUBLIC, ENVIRONMENTAL AND OCCUPATIONAL HEALTH

Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 2014;99(6):1114-22 [PubMed]
JCR Factor de Impacto: 5,814
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 6/68
JCR Categoría: HEMATOLOGY

Menezes J, Acquadro F, Wiseman M, Gómez López G, Salgado RN, Talavera Casanas JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-9 [PubMed]
JCR Factor de Impacto: 10,431
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 9/211
JCR Categoría: ONCOLOGY

Montes Moreno S, Batlle A, de Villambrosía SG, Sánchez Espiridión B, Cereceda L, González Barca E, et al. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. Haematologica. 2014;99(8):e138-41 [PubMed]
JCR Factor de Impacto: 10,431
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 9/211
JCR Categoría: ONCOLOGY

Morabito F, Bringhen S, Larocca A, Wijermans P, Mateos MV, Gimsing P, et al. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. Am J Hematol. 2014;89(4):355-62 [PubMed]
JCR Factor de Impacto: 3,798
JCR Cuartil: Q1
JCR Decil: D3
JCR Posición: 17/68
JCR Categoría: HEMATOLOGY

Mur P, Pineda M, Romero A, Del Valle J, Borrás E, Canal A, et al. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families. Clin Genet. 2014;85(3):260-6 [PubMed]
JCR Factor de Impacto: 3,931
JCR Cuartil: Q2
JCR Decil: D3
JCR Posición: 42/167
JCR Categoría: GENETICS & HEREDITY

Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-42 [PubMed]
JCR Factor de Impacto: 10,431
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 9/211
JCR Categoría: ONCOLOGY

Osorio Silla I, Brandáriz L, Rueda D, Marín JC, Perea J. Cirugía de la poliposis adenomatosa familiar atendiendo a sus bases moleculares. Gastroenterol Hepatol. 2014;37(10):565-7 [PubMed]
JCR Factor de Impacto: 0,838
JCR Cuartil: Q4
JCR Decil: D10
JCR Posición: 72/76
JCR Categoría: GASTROENTEROLOGY & HEPATOLOGY

Pinana JL, Montesinos P, Martino R, Vázquez L, Rovira M, López J, et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol. 2014;93(2):299-307 [PubMed]
JCR Factor de Impacto: 2,634
JCR Cuartil: Q2
JCR Decil: D5
JCR Posición: 32/68
JCR Categoría: HEMATOLOGY

Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-7 [PubMed]
JCR Factor de Impacto: 10,431
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 9/211
JCR Categoría: ONCOLOGY

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48 [PubMed]
JCR Factor de Impacto: 24,690
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 3/211
JCR Categoría: ONCOLOGY

Rojas SM, Díez Campelo M, Luno E, Cabrero M, Pedro C, Calabuig M, et al. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. Leuk Res. 2014;38(3):304-9 [PubMed]
JCR Factor de Impacto: 2,351
JCR Cuartil: Q3
JCR Decil: D6
JCR Posición: 40/68
JCR Categoría: HEMATOLOGY

Ruiz García R, Serrano M, Martínez Flores JA, Mora S, Morillas L, Martín Mola MA, et al. Isolated IgA anti- beta2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res. 2014;2014:704395-704395 [PubMed]
JCR Factor de Impacto: – –
JCR Cuartil: Q4
JCR Decil: D10
JCR Posición: 148/148
JCR Categoría: IMMUNOLOGY

Velasco Rodríguez D, Pérez Segura G, Jiménez Ubieto A, Rodríguez MA, Montejano L. Hemolytic disease of the newborn due to anti-jkb: case report and review of the literature. Indian J Hematol Blood Transfus. 2014;30(2):135-8.
JCR Factor de Impacto: 0,198
JCR Cuartil: Q4
JCR Decil: D10
JCR Posición: 67/68
JCR Categoría: HEMATOLOGY

Xicoy B, Jiménez M-J, García O, Bargay J, Martínez Robles V, Brunet S, et al. Results of treatment with azacitidine in patients aged ≥75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma. 2014;55(6):1300-3 [PubMed]
JCR Factor de Impacto: 2,891
JCR Cuartil: Q2
JCR Decil: D5
JCR Posición: 29/68
JCR Categoría: HEMATOLOGY

.

2015

Artículos

Blanes M, González JD, Lahuerta JJ, Ribas P, Lorenzo I, Boluda B, Sanz MA, De la Rubia J. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2015;56(2):415-9 [PubMed]

Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, et al. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. Int J Cancer. 2015;136(5):E351-8 [PubMed]

Carreño Tarragona G, Trapiello Valbuena F, Aranda Salom J, Martínez López J, Lumbreras C, Oliveira Ramírez E, et al. Antiphospholipid syndrome in a patient suffering from congenital dyserythropoietic anemia type III. Ann Hematol. 2015;94(8):1411-2 [PubMed]

Casado LF, García Gutiérrez JV, Massagué I, Giraldo P, Pérez Encinas M, De Paz R, et al. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. Cancer Med. 2015;4(7):995-1002
[PubMed]

Castro N, Rapado I, Ayala R, Martínez López J. CALR mutations screening should not be studied in splanchnic vein thrombosis. Br J Haematol. 2015;170(4):588-9 [PubMed]

Cibeira MT, Oriol A, Lahuerta JJ, Mateos M-V, de la Rubia J, Hernández MT, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015;170(6):804-13 [PubMed]

Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657-64 [PubMed]

Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100(10):1327-33 [PubMed]

Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Cytogenetics and long-term survival of pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2015;100(10):1327-33 [PubMed]

Domínguez Pinilla N, Baró Fernández M, González Granado LI. Hemophagocytic lymphohistiocytosis secondary to Epstein Barr virus and Leishmania co-infection in a toddler. J Postgrad Med. 2015;61(1):44-5 [PubMed]

Ferrà C, Sanz J, Díaz Pérez MA, Morgades M, Gayoso J, Cabrera JR, et al.; Grupo Español de Trasplante Hematopoyético (Geth) Spanish Society of Hematology. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56(3):656-62 [PubMed]

Font P, Loscertales J, Soto C, Ricard P, Novas CM, Martín Clavero E, et al. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. Ann Hematol. 2015;94(4):565-73 [PubMed]

Fulciniti M, Munshi NC, Martínez López J. Deep response in multiple myeloma: a critical review. Biomed Res Int. 2015;2015:832049 [PubMed]

Gallardo M, Lee HJ, Zhang X, Bueso Ramos C, Pageon LR, McArthur M, et al. hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies. Cancer Cell. 2015;28(4):486-99 [PubMed]

Hernández JA, Lahuerta JJ. Gammapatías biclonales: ¿significado clínico diferente? Rev Clin Esp. 2015;215(1):31-2 [PubMed]

López A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, et al. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep. 2015;4(2):64-9 [PubMed]

Martín Martín L, López A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015;6(22):19204-16 [PubMed]

Martínez López J, Jiménez A, Sánchez Calero J, Monteagudo D, Urbanowicz M, Cañamares Orbis I, et al. Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. Ann Hematol. 2015;94(7):1237-9 [PubMed]

Martínez López J, Paiva B, López Anglada L, Mateos MV, Cedena T, Vidríales MB, et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015;126(7):858-62 [PubMed]

Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez López J, Bladé J, et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev. 2015;29(6):387-403 [PubMed]

Mateos MV, Oriol A, Rosiñol L, De Arriba F, Puig N, Martín J, et al. Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica. 2015;100(8):1096-102 [PubMed]

Ocio EM, Herrera P, Olave MT, Castro N, Pérez Simón JA, Brunet S, et al. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II Panobidara study. Haematologica. 2015;100(10):1294-300 [PubMed]

Paíno T, Paiva B, Sayagués JM, Mota I, Carvalheiro T, Corchete LA, et al. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia. 2015;29(5):1186-94 [PubMed]

Paiva B, Chandia M, Puig N, Vidriales MB, Pérez JJ, López Corral L, et al. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica. 2015;100(2):e53-5 [PubMed]

Palumbo A, Avet Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9 [PubMed]

Panizo C, Rodríguez AJ, Gutiérrez G, Díaz FJ, González Barca E, De Oña R, et al. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study. Clin Lymphoma Myeloma Leuk. 2015;15(7):398-403 [PubMed]

Pineda M, González Acosta M, Thompson BA, Sánchez R, Gómez C, Martínez López
J, et al. Detailed characterization of MLH1 p.D41H and p.N710D variants coexisting in a Lynch syndrome family with conserved MLH1 expression tumors. Clin Genet. 2015;87(6):543-8 [PubMed]

Ribera J, Morgades M, Zamora L, Montesinos P, Gómez Seguí I, Pratcorona M,
et al.; Spanish PETHEMA Group and the Spanish Society of Hematology. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015;121(21):3809-17 [PubMed]

Ríos R, Lupiáñez CB, Campa D, Martino A, Martínez López J, Martínez-Bueno M, et al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma. Endocr Relat Cancer. 2015;22(4):545-59 [PubMed]

San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015;100(10):1334-9 [PubMed]

Seguí N, Mina LB, Lázaro C, Sanz Pamplona R, Pons T, Navarro M, et al. Germline mutations in FAN1 cause hereditary colorectal cancer by impairing DNA repair. Gastroenterology. 2015;149(3):563-6 [PubMed]

Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Díez Campelo M, et al. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. Lancet Haematol. 2015;2(6):e260-6 [PubMed]

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun. 2015;6:7539 [PubMed]

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, et al. Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun. 2015;6:10203 [PubMed]

Congresos

Alonso Álvarez S, Alcoceba M, Magnano L, García Álvarez M, Andrade M, Coutinho R, et al. Transformation of follicular lymphoma incidence in rituximab era: multicenter retrospective analysis of the Spanish Group of Lymphoma and Transplantation Autologous Marrow Bone (Geltamo). Haematologica. 2015;100:10-10 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Alonso Álvarez S, Alcoceba M, Magnano L, García Álvarez M, Andrade M, Coutinho R, et al. Treatment of folicular lymphoma transformed: multicentric retrospective analysis of the Spanish Group of Lymphoma and Autologous Transplant of Medula Osea (Geltamo). Haematologica. 2015;100:162-3 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Alonso Fernández R, Ayala Díaz R, De la Serna Torroba FJ, Grande García C, Rodríguez Izquierdo A, Martínez Sánchez P, et al. Analysis of results obtained in clinical trial phase I/II for haematological pathology. Experience in the Hospital 12th October. Haematologica. 2015;100:117-8 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Arana P, Paiva B, Puig N, Cedena T, Cordón L, Vidriales MB, et al. Prognostic value of immune profiling multiple myeloma patients during minimal residual disease monitoring in the pethema. Bllod. 2015;126(23) (57. Annual Meeting of the American-Society-of-Hematology. Orlando, FL).

Ballesteros J, Martínez López J, Martínez D, Serrano J, Fernández Abellán P, García Boyero R, et al. Test of personalized medicine for pharmacology ex vivo in native environment for acute myeloid leukemia. Haematologica. 2015;100:145-145 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Besses C, Bello López JL, De la Serna J, Hernández Boluda JC, Loscertales J, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe: observational study of 3649 patients of high risk (Exels). Haematologica. 2015;100:29-29 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Canal López A, Rueda D, Atanasio P, Díaz Rodríguez E, Martinez J. Pharmacological inhibition of met destroys multiple myeloma clonogenic tumor cell. Haematologica. 2015;100:61-61 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Canal López A, Rueda D, Martínez LJ. Healthy bone marrow stromal cells induce apoptosis of cells of myeloma cooperating with antimyeloma drugs. Haematologica. 2015;100:63-4 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Carreño Gómez-Tarragona G, Miras Calvo F, Montejano Ortega L, Cedena Romero MT, Martínez López J. Daratumumab interferes in the pre-transfusion tests in the blood bank. Haematologica. 2015;100:36-36 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

De Lacalle Juega LA, Cedena Romero MT, Ayala Díaz R, Martínez López J, Gilsanz Rodríguez F. Assessment of impact of TP53 in different haematological neoplasias. Haematologica. 2015;100:81-2 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

De la Iglesia S, Cedena T, Gómez Roncero M, Arrizabalaga B, Villegas A. How we treat surgical Pnh patients: experience of the Hpn Spanish Registry. Haematologica. 2015;100:30-1 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

García Gutiérrez V, Colom B, Kreutzman A, Casado L, Sánchez Guijo F, Ayala R, et al. Induced lymphocytosis following the intake of dasatinib is associated with the inhibition of lymphocytary migration and modification of the expression of chemokine receptors, and such inhibition appears to be associated with an early response. Preliminary results of the clinical trial phase 2 dasapost. Haematologica. 2015;100:25-6 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

García Sanz R, Sureda A, González AP, Salar A, Rodríguez A, De La Cruz F, et al. Evaluation of the brenutximab vedotin regime and eshap (breshap) in lymphoma primary resistant Hodgkin’s or in first relapse: results preliminary a trial phase I-II of the Spanish Group of Lymphomas and Transplantation of Bone Marrow (Geltamo). Haematologica. 2015;100:9-9 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Genesca Ferrer E, Berbis Serrat G, Morgades Delafe M, Ribera Sala J, Guardia Sánchez R, Montesinos Fernández P, et al. Identification of alterations in the number of copies (CNA) and implied mutations in the progresion and relapse of LAL-T. Haematologica. 2015;100:150-150 (57. Congreso Nacional de

Gómez Calafat M, Álvarez Larrán A, Ferrer Marín F, Raya José M, Boque C, Kerguelen A, et al. Spanish Record of Myelofibrosis: descriptive analysis. Haematologica. octubre de 2015;100:189-189 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Gómez Rojas S, Quiroz Cervantes K, Ayala Díaz R, González FA, Martínez López J, Gilsanz Rodríguez F. Quadrupling of the gene of alpha globin in a case of thalassemia intermedia. Haematologica. 2015;100:96-7 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Grande García C, Kantarjian Hagop M, Stein AS, Bargou Ralf C, Larson RA, Stelljes M, et al. Safety and activity of blinatumomab in two phase-2 trials in elderly patients with relapsed or refractory B-precursor acute lymboblastic leukemia. Haematologica. 2015;100:19-19 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Jiménez Segura R, Rosinol L, Teruel A, De la Rubia J, Mateos M, Hernández MT, et al. Results of 66 patients with extramedullary plasmacytomas (PE) included. Haematologica. 2015;100:42-42 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Jiménez Segura R, Rosinol Dachs L, Oriol Rocafiguera A, Blanchard Rodríguez MJ, Palomera Bernal L, Mateos Manteca M, et al. Treatment of renal insufficiency in patients with multiple myeloma diagnosed again with bortezomib and dexamethasone: results of a study phase Ii of the Pethema/ Gem (Renvel) Group. Haematologica. 2015;100:47-8 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Jiménez Ubieto A, Bellosillo B, Gallardo M, Ayala Díaz R, Barrio S, Besses C, et al. Deregulation of micro RNA’s in patients with polycythemia vera (PV) and essential thrombosis (TE). Haematologica. 2015;100:191-191 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Jiménez Ubieto A, García Gigorro R, Grande García C, Martínez Sánchez P, Rodríguez Izquierdo A. Sick haemato-oncological admitted in an Intensive Care Unit (UCI). Short and long term prognostics. A reflection on its efficiency. Haematologica. 2015;100:117-117 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Jiménez Ubieto A, Grande García C, López Guillermo A, Salar A, Caballero D, Yáñez L, et al. Characteristics of relapse after the autologous transplant of hematopoietic progenitors (TAPH) in folicular Lymphoma (LF): an analysis with long follow up of the Geltamo Record. Haematologica. 2015;100:13-4 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Jiménez Ubieto A, Grande García C, López Guillermo A, Salar A, Caballero D, Yáñez L, et al. Impact of previous exposure to rituximab in patients with follicular lymphoma (LF) intensified with autologous transplant of hematopoietic progenitors (TAPH): a retrospective analysis of the record of Geltamo. Haematologica. 2015;100:166-7 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Leivas A, Pérez Martínez A, Blanchard MJ, Campana D, Lahuerta JJ, Martínez López J. Repeated infusions of Nk autologous cells activated and expanded in combination with antimyeloma drugs: a new therapeutic option against refractory multiple myeloma. Haematologica. 2015;100:50-1 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

López Anglada L, Alcoceba M, García Álvarez M, Díaz Gálvez FJ, Bourgeois M, Queizan JA, et al. Impact of the mutational state of IGHV in lymphoproliferative syndromes CD19+CD5+(no LLC) with and without T (11,14): immunophenotypic characterization and clinical behaviour. Haematologica. 2015;100:155-155 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

López Anglada L, Cueto Felgueroso C, Mateos María V, Rosinol L, Oriol A, Teruel A, et al. Value of the ratio of free light chains and potential clinical utility. Haematologica. 2015;100:43-4 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

López-Santamaría Castro C, Valdivielso López A, Cuadrado Orden I, Luno Fernández E, Morán Jiménez MJ, Sánchez M. Iron overload in young patient. Haematologica. 2015;100:94-5 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Martín Martín L, López A, Vidriales B, Caballero MD, Silva Rodrigues A, Ferreira S, et al. Clinical-biological characteristics of the neoplasms of blastic plasmocytoid dendritic cells in function of the maturation stage of the tumour cells. Haematologica. 2015;100:138-138 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Mateos Manteca M, De la Rubia J, Martínez J, Pérez Simón JA, Garrido T. Current management of the treatment of multiple myeloma in Spain: meeting of experts of 41 hospitals. Haematologica. 2015;100:248-9 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Montesdeoca RS, Kerguelen A, Hernández Boluda JC, Pérez Encinas M, Aragües P, Ferrer F, et al. Treatment of polycythemia vera with hydroxyurea: rate of response, resistance/ intolerance and evolutive complications in a series of 1165 patients. Haematologica. 2015;100:24-24 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Onecha De La Fuente ME, Rapado I, Barrio S, Castro N, Alonso R, Sánchez JM, et al. Mutational profile study of diagnosis of acute myeloid leukemia (AML) by next generation sequencing (NGS). Haematologica. 2015;100:19-20 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Osorio Prendes S, Casado LF, Giraldo P, Redondo S, Villalón L, Coza A, et al. Chronic myeloid leukemia (LMC) is currently diagnosed in less advanced situation, and in Spain in low risk stages than in neighbouring countries. Haematologica. 2015;100:193-193 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Quiroz Cervantes KS, Guillén Rienda C, Ayala Díaz R, Martínez López J. Expression of RPS14 in the myelodysplastic syndromes. Haematologica. 2015;100:188-188 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Ribera J, Morgades M, Zamora L, Granada I, Junca J, Genesca E, et al. Alterations in the number of copies in adul patients with acute lymphoblastic leukemia of B precursors in 1(A) relapse treated with care protocols of the Pethema Group. Haematologica. 2015;100:148-148 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Rodríguez Rodríguez M, Martín Clavero E, Gilsanz Rodríguez F. Role of aspirated-biopsy of medulla ossea in the diagnosis of primary immune dethrombopenia. Haematologica. 2015;100:297-8 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Ruiz Heredia Y, Sánchez Vega B, Rapado I, Ayala R, García Sanz R, Jiménez C, et al. Implementation of a multiple myeloma specific custom 77-gene mutation panel. Haematologica. 2015;100:60-60 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Ruiz Xiville N, Morgades M, Vives S, Hoyos M, Aventin A, Espinet B, et al. Prognostic significance of hyperdiploids in acute myeloid leukemia (LAM). Haematologica. 2015;100:145-6 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Sánchez Pina JM, Rodríguez Rodríguez M, Martín Clavero E, Gilsanz F. Hemophagocytosis in medulla ossea and its relation with the hemophagocytic syndrome. Diagnosis and etiology. Haematologica. 2015;100:224-5 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Sánchez-Vega Carrión B, Ruiz Y, Barrios S, Maldonado R, Marín C, Rapado I, et al. Prognostic value of sequencing-based minimal residual disease detection. Haematologica. 2015;100:60-60 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Talarn Forcadell C, Escoda Teigell L, Montesinos Fernández P, Amutio Díez E, Pinan Frances MA, Giménez Pérez T, et al. Acute promyelocytic leukemia variant. Incidence and characteristics of the reported cases in the Pehtema-LPA case. Haematologica.  2015;100:144-144 (57. Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia. Valencia).

Responder

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión /  Cambiar )

Google photo

Estás comentando usando tu cuenta de Google. Cerrar sesión /  Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión /  Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión /  Cambiar )

Conectando a %s